What is Celgene Corporation's stock symbol?
Celgene Corporation trades on the NASDAQ under the ticker symbol "CELG."
When did Celgene Corporation's stock split? How did Celgene Corporation's stock split work?
Celgene Corporation shares split on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were payable to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene Corporation stock prior to the split would have 200 shares after the split.
Where is Celgene Corporation's stock going? Where will Celgene Corporation's stock price be in 2017?
28 brokerages have issued 1 year price objectives for Celgene Corporation's shares. Their forecasts range from $91.00 to $162.00. On average, they expect Celgene Corporation's stock price to reach $139.71 in the next twelve months.
When will Celgene Corporation announce their earnings?
Celgene Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.
What are analysts saying about Celgene Corporation stock?
Here are some recent quotes from research analysts about Celgene Corporation stock:
- Robert W. Baird analysts commented, "Celgene reported positive top-line data from the SUNBEAM trial of ozanimod in multiple sclerosis. Though no numbers were provided, it looks like the primary and key secondary endpoints were met, with a similar safety profile versus the Phase 2 studies. Though we find the lack of additional safety issues encouraging, success also depends on ability to compete with Gilenya, Tecfidera, and Roche's Ocrevus on efficacy. More complete data won't be available until later this half." (2/17/2017)
According to Zacks Investment Research, "Celgene’s fourth quarter results were disappointing, with the company missing on both the top and the bottom line. Nevertheless, Revlimid continued to outperform in the quarter on the back of market share gains and increased duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – also performed well. Both Otezla and Pomalyst achieved blockbuster status in 2016 recording over $1 billion in sales. Meanwhile, Celgene continues to progress with its label expansion efforts and pipeline development. Label expansion of approved drugs would boost its revenues. Sales of Revlimid are expected to maintain momentum along with Otezla and Pomalyst. The company’s outlook for 2017 was encouraging. Shares of Celgene have outperformed the industry in the past one year. Estimates have gone up post Q4 results. However, Celgene is highly dependent on Revlimid for growth. Stiff competition in target markets is another concern." (2/1/2017)
- Jefferies Group LLC analysts commented, "Though updates were mostly incremental given recent pre-reporting, the review of sales dynamics, 2017 guidance, and pipeline progress reaffirms our expectation for best-in-class medium-term growth from healthy core franchises. We expect continued strong execution throughout the year and lower-risk catalysts to drive appreciation towards levels reflecting underappreciated prospects of their products and portfolio." (1/27/2017)
- Cann analysts commented, "Celgene reported a strong quarter and year-end that was in line with expectations. The outlook for Celgene's clinical programs, based on today's update, remain very encouraging and support long-term sales and earnings growth for the company. We are modestly increasing near-term estimates, which along with a higher group PEG rate, is leading us to increase our target price to $148 from $141." (1/26/2017)
Cantor Fitzgerald analysts commented, "Waiting for Guidance. We expect CELG to issue guidance for 2017 in early January. Recent guidance history has involved modest guidance only to creep up through the year, which we think could occur again in 2017. We are not expecting pressure on long term guidance, and continue to value the strength of cash flow, along with share repurchases and possible upside from the pipeline. Our new 2016 forecast goes to $5.93 and our 2017 EPS forecast goes to $7.05. Revlimid Keeps on Going. A key component to CELG’s near term growth is the IMID franchise, anchored by REVLIMID and assisted by Pomalyst. The dynamics in this market (more lines of therapy, longer duration) bode well for continued growth of the multi-billion dollar franchise." (1/6/2017)
Who owns Celgene Corporation stock?
Celgene Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (4.10%), FMR LLC (2.21%), Franklin Resources Inc. (1.34%), Edgewood Management LLC (1.24%), Janus Capital Management LLC (1.10%) and Polen Capital Management LLC (0.56%). Company insiders that own Celgene Corporation stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin and Thomas O Daniel.
Who sold Celgene Corporation stock? Who is selling Celgene Corporation stock?
Celgene Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Janus Capital Management LLC, Renaissance Technologies LLC, FIL Ltd, Franklin Resources Inc., Calamos Advisors LLC, Nicholas Co. Inc. WI and Eventide Asset Management LLC. Company insiders that have sold Celgene Corporation stock in the last year include Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Richard W Barker and Robert J Hugin.
Who bought Celgene Corporation stock? Who is buying Celgene Corporation stock?
Celgene Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Asset Management One Co. Ltd., Polen Capital Management LLC, State Street Corp, Elkfork Partners LLC, Fred Alger Management Inc., Tyers Asset Management LLC, Russell Investments Group Ltd. and Congress Asset Management Co. MA. Company insiders that have bought Celgene Corporation stock in the last two years include Corp /De/ Celgene and Michael W Bonney.
How do I buy Celgene Corporation stock?
Shares of Celgene Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Celgene Corporation stock cost?
One share of Celgene Corporation stock can currently be purchased for approximately $121.16.